Next undiscovered and brutally underpriced stock with significant upside potential ...GL EYEN = Market Cap $51 M --Cash $18 M-- 1 Big drug close to NDA submission another 2 Drug in Phase 3 with readouts by next year 1 Big Drug is NDA ready -- Another 2 Big Drugs in Phase 3 with readouts expected in 2H 2020 -- MASSIVE Insider buying --Low float Stock -- CEO/CMO Ianchulev is the great scientist who lead the development of themega Blockbuster Lucentis =BRUTALLY UNDERPRICED STOCK WITH MASSIVE UPSIDE POTENTIAL !!! GL Eyenovia (EYEN) Market Cap $51 M Cash $18.4 M Price $3 Shares Out 17.1 M Presentation http://ir.eyenoviabio.com/static-files/0ec5c485-6161-4048-95fa-9202d360aae8 Insider buying http://openinsider.com/search?q=eyen MicroStat (Indication: Mydriasis) File NDA $300 M+ Market Opportunity MicroLine (indicationresbyopia) Initiate and Complete Phase III VISION Study $2 B+ Market Opportunity MicroPine (Indication: Progressive Myopia) Complete Phase III CHAPERONE Enrollment $ 5B+ Market Opportunity
Great buying opp after the Pullback from over $4+ ...Stock is dirt cheap and has a very attractive product pipeleine ..Next time likely to run closer to $10 or higher
This low float stock has the potential to move like AXSM which i recommended here at $3.60 now trading above $70+ ..One of the hottest and cheapest smallcap Biotech listed on Nasdaq .GL
Market Cap $65 million / NDA submission for first drug likely next Quarter / 2 more BIG Drugs in Phase 3 with Data in short term ....Dirt cheap low float stock MicroStat (Indication: Mydriasis) File NDA $300M+ Market Opportunity MicroLine (indicationresbyopia) Initiate and Complete Phase III VISION Study $2B+ Market Opportunity MicroPine (Indication: Progressive Myopia) Complete Phase III CHAPERONE Enrollment $5B+ Market Opportunity
$5.40 ..BIG FDA Decision in 23 days + another 2 potential Blockbuster in Phase 3 nearing readout ..This low float stock could move toward $7-8 ahead of the FDA Decision and with approval the stock could hit $10 ..GL Pipeline https://assets.wallstreet-online.de...hot-2021-07-27-at-23-04-33-powerpointpres.png 2 Healthcare Stocks With Big Catalysts in October https://finance.yahoo.com/news/2-healthcare-stocks-big-catalysts-130031893.html The FDA is expected to make its decision on Eyenovia’s NDA for MydCombi shortly, with a PDUFA date set for October 28. A positive decision will clear the path for commercialization, targeting the extensive potential patient base. Ahead of the big day, Ladenburg Thalmann’s Matthew Kaplan backs the drug’s chances and anticipates a successful market entry. “We expect MicroStat (Mydcombi) NDA approval and market launch in the U.S. in 4Q21,” the analyst wrote. “The commercial strategy differs from traditional launches as Eyenovia will not hire a sales force; instead, they will maintain ~10 key account managers to initially focus on the largest practices…. With Eyenovia’s plan to price MicroStat on parity to the current eye drops based on their market research, and with an estimated 80 million dilated eye exams and ~4 million surgeries requiring dilation performed each year, we believe it could represent a significant market opportunity for MicroStat.” Kaplan gives EYEN shares a Buy rating, with a $19 price target
